Article: Lunesta Data to Be Presented at American Psychiatric Association Annual Meeting.

MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that Phase III/IV clinical data for LUNESTA(TM) brand eszopiclone for the treatment of insomnia will be presented at the American Psychiatric Association (APA) annual meeting in Atlanta.

Posters will be presented on May 25, 2005 in the Georgia World Congress Center, Level 3, Rooms B302-B305 between 12:00 pm and 2:00 pm. The posters are entitled:

--Adjunctive Eszopiclone and Fluoxetine in Major Depressive Disorder (MDD) and Insomnia: Depression Effects

--Adjunctive Eszopiclone With Fluoxetine for MDD and Insomnia: Sleep Effects

--Effect of Eszopiclone on Sleep Parameters ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!